Matthew Winton
Fortune : 46 500 $ au 30/06/2026
Fortune : 46 500 $ au 30/06/2026
Matthew J.
Winton currently works at CervoMed, Inc., as Chief Commercial & Business Officer from 2025.
Dr. Winton also formerly worked at Decision Resources, Inc., as Research Analyst from 2008 to 2010 and Inozyme Pharma, Inc., as Chief Operating Officer & Senior Vice President from 2023 to 2025.
Dr. Winton received his Masters Business Admin degree in 2011 from Boston University, undergraduate degree in 1999 from York University, and doctorate degree in 2004 from the University of Montréal.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CERVOMED INC. 0,11 % | 11/02/2026 | 15 000 ( 0,11 % ) | 46 500 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CERVOMED INC. | Corporate Officer/Principal | 07/10/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| INOZYME PHARMA, INC. | Directeur des opérations | 01/07/2025 |
Decision Resources, Inc.
Decision Resources, Inc. Investment ManagersFinance Provides investment research | Analyst-Equity | 01/04/2010 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Decision Resources, Inc.
Decision Resources, Inc. Investment ManagersFinance Provides investment research | Finance |
University of Montréal
University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Inozyme Pharma, Inc.
Inozyme Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines | Health Technology |
CervoMed, Inc.
CervoMed, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that develops novel therapies | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national